- Home
- CADL vs SNN Comparison
CADL vs SNN Comparison
Compare CADL & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CADL | SNN |
|---|---|---|
| Founded | 1999 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.3M | 14.3B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CADL | SNN |
|---|---|---|
| Price | $4.98 | $32.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | $19.71 | ★ $36.25 |
| AVG Volume (30 Days) | ★ 1.3M | 786.8K |
| Earning Date | 03-12-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.35% |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.36 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $23.91 |
| 52 Week High | $8.66 | $38.79 |
Technical Indicators
Market Signals| Indicator | CADL | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 34.16 |
| Support Level | $4.58 | $29.27 |
| Resistance Level | $5.42 | $33.89 |
| Average True Range (ATR) | 0.25 | 0.63 |
| MACD | 0.02 | -0.30 |
| Stochastic Oscillator | 53.33 | 6.34 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.